Angion Biomedica Corp.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.angion.com
Clinical Trials
17
Active:3
Completed:2
Trial Phases
3 Phases
Phase 1:7
Phase 2:8
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 2
8 (50.0%)Phase 1
7 (43.8%)Phase 3
1 (6.3%)Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Angion Biomedica Corp
- Target Recruit Count
- 20
- Registration Number
- NCT05387785
Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Angion Biomedica Corp
- Target Recruit Count
- 16
- Registration Number
- NCT04958187
- Locations
- 🇺🇸
Hennepin County Medical Center (HCMC), Minneapolis, Minnesota, United States
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Angion Biomedica Corp
- Target Recruit Count
- 100
- Registration Number
- NCT04939116
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Amicis Reserach Center, Vacaville, California, United States
🇺🇸South Florida Research Institute, Lauderdale Lakes, Florida, United States
A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777
Phase 1
- Conditions
- Healthy
- Interventions
- Drug: carbon-14-[14C]-ANG-3777
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Angion Biomedica Corp
- Target Recruit Count
- 6
- Registration Number
- NCT04931524
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, Nottinghamshire, United Kingdom
Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval
Phase 1
- Conditions
- Healthy Volunteer
- Interventions
- Drug: ANG-3777 (Therapeutic Dose)Drug: PlaceboDrug: ANG-3777 (Supra-therapeutic Dose)
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Angion Biomedica Corp
- Target Recruit Count
- 48
- Registration Number
- NCT04898907
- Locations
- 🇺🇸
Quotient Sciences, Miami, Florida, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found